Samsung Biologics said that it has entered into a contract developing organization (CDO) agreement with Taiwan’s Aprinoia Therapeutics to develop a treatment for Alzheimer's disease.
|Samsung Biologics headquarters in Songdo, Incheon.|
Aprinoia Therapeutics is a bio-venture that develops diagnostic equipment and treatments for degenerative neurological diseases. It is a leading biotechnology company developing novel therapeutics using target-specific pathological tau aggregates in treating Alzheimer's disease.
Under the accord, Samsung Biologics will provide development services, ranging from Aprinoia's cell line development of candidates for Alzheimer's treatment to process development, production of clinical samples, and submission of clinical trial plans.
The company will also produce global non-clinical and clinical materials in the future.
Samsung Biologics is pursuing to attract new customers in Greater China based on a partnership agreement with Aprinoia.
To this end, the company has established a batch supply system for the entire process of biopharmaceutical production, such as cell line and process development, small-scale production of clinical substances, mass production of commercial products, finished medicine production, consignment analysis, and quality control.
"We are actively discussing additional contracts with more than 20 Chinese customer firms," a company official said. "We are solidifying our position as a global leader by expanding partnerships with several global customers."
Samsung Biologics CEO Kim Tae-han said, "We look forward to working with Aprinoia to accelerate the development of Alzheimer's treatment."
<© Korea Biomedical Review, All rights reserved.>